Sepracor to cut sales force jobs

Share this article:

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008.

“We have examined our sales organization in depth,” Adrian Adams, Sepracor's CEO said in a telephone conference with analysts today. “We believe we have an opportunity to significantly raise the performance level so that we can see a positive impact in 2008. We believe that this is an example where we'll be able to do more with less.”

Meanwhile, Sepracor's third quarter profits fell 33% driven by declining revenue from asthma drug Xopenex.

Sales of Xopenex declined for the second straight quarter since Medicare cut reimbursement rates for the drug.

Sales of sleeping pill Lunesta, Sepracor's top-selling product, were up 14% during the quarter.

For more details on Sepracor's third quarter earnings, click here.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.